scholarly journals Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial

2021 ◽  
Vol 4 (4) ◽  
Author(s):  
Arif Awan ◽  
Bassam Basulaiman ◽  
Carol Stober ◽  
Mark Clemons ◽  
Dean Fergusson ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Randomized Trial ◽  
Oral Magnesium

scholarly journals A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias

2017 ◽  
Author(s):  
Pamela L. Lutsey ◽  
Lin Y. Chen ◽  
Anne Eaton ◽  
Melanie Jaeb ◽  
Kyle D. Rudser ◽  
...  
Keyword(s):  
Placebo Group ◽  
Pilot Study ◽  
Randomized Trial ◽  
Magnesium Concentration ◽  
Magnesium Supplementation ◽  
Supplement Group ◽  
Gastrointestinal Problems ◽  
Magnesium Supplement ◽  
Oral Magnesium

AbstractBackgroundMagnesium is believed to have a physiologic role in cardiac contractility, and evidence from epidemiologic and clinical studies has suggested that low serum concentrations of magnesium may be associated with increased risk of atrial fibrillation (AF).ObjectiveAs part of the planning effort for a large randomized trial to prevent AF with magnesium supplementation, we conducted a 12-week pilot study to assess adherence to oral magnesium supplementation and matching placebo, estimate the effect on circulating magnesium concentrations, and evaluate the feasibility of using an ambulatory monitoring device (ZioPatch) for assessing premature atrial contractions (PACs), a predictor of AF.DesignDouble-blind randomized pilot clinical trial comparing supplementation with 400 mg magnesium oxide daily (versus placebo) over 12 weeks of follow-up. The ZioPatch was applied for 14 days at baseline and the end of follow-up. Adherence to the assigned treatment, and changes in PACs, serum magnesium concentration, glucose and blood pressure were assessed.ResultsA total of 59 participants, 73% women and average age 62 years, were randomized. 98% of participants completed follow-up. Those assigned to the magnesium supplement took 75% of tablets as compared to 83% for those in the placebo group. Change in magnesium concentrations was significantly greater for those given magnesium supplement compared to placebo (0.07; 95% confidence interval (CI): 0.03, 0.12 mEq/L; p = 0.002). ZioPatch was worn for an average of 13.0 of the requested 14 days at baseline; at the end of follow-up, the average number of days of monitoring was 13.0 days for the magnesium supplement group and 12.7 days for the placebo group. For log PAC burden (episodes per hour), the average change from baseline was −0.05 (95% CI: −0.31, 0.20) for those randomized to magnesium supplement and 0.04 (95% CI: −0.24, 0.31) for those randomized to placebo (p=0.79 for difference). Gastrointestinal problems were reported by 50% of participants in the magnesium supplement group and 7% in the placebo group. Only one person in the magnesium supplement group and none in the placebo group experienced adverse events which led to treatment discontinuation.ConclusionsIn this pilot randomized clinic trial, although gastrointestinal side effects to the magnesium supplement were common, adherence, measured by pill counts, was very good and, as a consequence, magnesium concentrations were greater for those randomly assigned to the magnesium supplement compared to placebo. Participant acceptance of the planned monitoring with ZioPatch was also very good. While the difference in the change in PACs was not significant, this pilot study was small, short-term, and did not include participants at high risk of AF. Thus, we could not reliably evaluate the effect of magnesium supplementation on PACs.Clinicaltrials.gov registrationNCT02837328

scholarly journals A Pilot Randomized Trial of Oral Magnesium Supplementation on Supraventricular Arrhythmias

Nutrients ◽  
2018 ◽  
Vol 10 (7) ◽  
pp. 884 ◽  
Author(s):  
Pamela Lutsey ◽  
Lin Chen ◽  
Anne Eaton ◽  
Melanie Jaeb ◽  
Kyle Rudser ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Supraventricular Arrhythmias ◽  
Magnesium Supplementation ◽  
Oral Magnesium

Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-controlled, randomized trial

2011 ◽  
Vol 13 (3) ◽  
pp. 281-284 ◽  
Author(s):  
F. C. Mooren ◽  
K. Krüger ◽  
K. Völker ◽  
S. W. Golf ◽  
M. Wadepuhl ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Randomized Trial ◽  
Magnesium Supplementation ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Oral Magnesium

scholarly journals Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia

2019 ◽  
Vol 37 (31) ◽  
pp. 2892-2898 ◽  
Author(s):  
Gerald A. Soff ◽  
Yimei Miao ◽  
Gemma Bendheim ◽  
Jeanette Batista ◽  
Jodi V. Mones ◽  
...  
Keyword(s):  
Platelet Count ◽  
Cancer Treatment ◽  
Usual Care ◽  
Randomized Trial ◽  
Dose Reduction ◽  
Solid Tumors ◽  
Prospective Trial ◽  
End Point ◽  
The Mean ◽  
Chemotherapy Patients

PURPOSE Chemotherapy-induced thrombocytopenia (CIT) leads to delay or reduction in cancer treatment. There is no approved treatment. METHODS We conducted a phase II randomized trial of romiplostim versus untreated observation in patients with solid tumors with CIT. Before enrollment, patients had platelets less than 100,000/μL for at least 4 weeks, despite delay or dose reduction of chemotherapy. Patients received weekly titrated romiplostim with a target platelet count of 100,000/μL or more, or were monitored with usual care. The primary end point was correction of platelet count within 3 weeks. Twenty-three patients were treated in a randomization phase, and an additional 37 patients were treated in a single-arm, romiplostim phase. Resumption of chemotherapy without recurrent CIT was a secondary end point. RESULTS The mean platelet count at enrollment was 62,000/μL. In the randomization phase, 14 of 15 romiplostim-treated patients (93%) experienced correction of their platelet count within 3 weeks, compared with one of eight control patients (12.5%; P < .001). Including all romiplostim-treated patients (N = 52), the mean platelet count at 2 weeks of treatment was 141,000/μL. The mean platelet count in the eight observation patients at 3 weeks was 57,000/μL. Forty-four patients who achieved platelet correction with romiplostim resumed chemotherapy with weekly romiplostim. Only three patients (6.8%) experienced recurrent reduction or delay of chemotherapy because of isolated CIT. CONCLUSION This prospective trial evaluated treatment of CIT with romiplostim. Romiplostim is effective in correcting CIT, and maintenance allows for resumption of chemotherapy without recurrence of CIT in most patients.

A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 8031-8031 ◽  
Author(s):  
D. P. Steensma ◽  
R. Molina ◽  
J. A. Sloan ◽  
D. A. Nikcevich ◽  
P. L. Schaefer ◽  
...  
Keyword(s):  
Treatment Group ◽  
Cancer Treatment ◽  
Randomized Trial ◽  
Phase Iii ◽  
North Central ◽  
Patients With Cancer

A randomized trial of weekly high-dose calcitriol and weight-bearing exercise for cancer treatment–induced bone loss (CTIBL) and bone metabolism in ER+ breast cancer (BC) patients.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 9100-9100
Author(s):  
L. J. Peppone ◽  
R. N. Rosier ◽  
K. M. Mustian ◽  
M. N. Ling ◽  
A. Huston ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Loss ◽  
Cancer Treatment ◽  
Randomized Trial ◽  
Bone Metabolism ◽  
Weight Bearing ◽  
High Dose

154: Acute Toxicity of Ultrahypofractionation Compared to Moderate Hypofractionation in Prostate Cancer Treatment – a Randomized Trial

2021 ◽  
Vol 163 ◽  
pp. S65
Author(s):  
Winkle Kwan ◽  
Samar Hejazi ◽  
Gaurav Bahl ◽  
David Kim ◽  
Allison Ye ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Acute Toxicity ◽  
Cancer Treatment ◽  
Randomized Trial ◽  
Prostate Cancer Treatment ◽  
Moderate Hypofractionation

scholarly journals A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment

Cancer ◽  
2011 ◽  
Vol 118 (2) ◽  
pp. 500-509 ◽  
Author(s):  
Leslie R. Schover ◽  
Andrea L. Canada ◽  
Ying Yuan ◽  
Dawen Sui ◽  
Leah Neese ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Randomized Trial ◽  
Localized Prostate Cancer ◽  
Prostate Cancer Treatment ◽  
Sexual Counseling

Oral Magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial

2004 ◽  
Vol 30 (3) ◽  
pp. 253-258 ◽  
Author(s):  
F Guerrero-Romero ◽  
HE Tamez-Perez ◽  
G González-González ◽  
AM Salinas-Martínez ◽  
J Montes-Villarreal ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Insulin Sensitivity ◽  
Randomized Trial ◽  
Magnesium Supplementation ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Oral Magnesium
Sign in / Sign up

Export Citation Format

Share Document